These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7020113)

  • 1. Production of specific antibody to Cryptococcus neoformans by hybridomas in vitro.
    Hall NK; Blackstock R
    Sabouraudia; 1981 Jun; 19(2):157-60. PubMed ID: 7020113
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of murine natural killer cells by Cryptococcus neoformans.
    Bartizal KF; Salkowski CA; Balish E
    Prog Clin Biol Res; 1985; 181():333-6. PubMed ID: 3895239
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antibody response to fungal melanin in mice.
    Nosanchuk JD; Rosas AL; Casadevall A
    J Immunol; 1998 Jun; 160(12):6026-31. PubMed ID: 9637518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel monoclonal antibody recognizing beta(1-3) glucans in intact cells of Candida and Cryptococcus.
    Kondori N; Edebo L; Mattsby-Baltzer I
    APMIS; 2008 Oct; 116(10):867-76. PubMed ID: 19132980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
    van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
    Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
    Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
    Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin testing of guinea pigs and footpad testing of mice with a new antigen for detecting delayed hypersensitivity to Cryptococcus neoformans.
    Murphy JW; Gregory JA; Larsh HW
    Infect Immun; 1974 Feb; 9(2):404-9. PubMed ID: 4593343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the repertoire of anti-NP antibodies in C57BL/6 mice by cell fusion. I. Characterization of antibody families in the primary and hyperimmune response.
    Reth M; Hämmerling GJ; Rajewsky K
    Eur J Immunol; 1978 Jun; 8(6):393-400. PubMed ID: 97089
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response to Cryptococcus neoformans proteins in rodents and humans.
    Chen LC; Goldman DL; Doering TL; Pirofski La; Casadevall A
    Infect Immun; 1999 May; 67(5):2218-24. PubMed ID: 10225877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans.
    Mody CH; Paine R; Jackson C; Chen GH; Toews GB
    J Immunol; 1994 Apr; 152(8):3970-9. PubMed ID: 8144964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide-dependent killing of Cryptococcus neoformans by B-1-derived mononuclear phagocyte.
    Ghosn EE; Russo M; Almeida SR
    J Leukoc Biol; 2006 Jul; 80(1):36-44. PubMed ID: 16670124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
    Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
    J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The isolation of monoclonal antibodies to Cryptococcus neoformans antigens].
    Khrapova NP; Lesovoĭ VS; Prokhvatilova EV; Stupenko LN; Zharkova SF
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):70-4. PubMed ID: 10876856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.
    Ikeda R; Nishimura S; Nishikawa A; Shinoda T
    Clin Diagn Lab Immunol; 1996 Jan; 3(1):89-92. PubMed ID: 8770510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The evaluation of the specific type of capsular polysaccharide of Cryptococcus neoformans as an immunogen and positive-control antigen].
    Toraño Peraza GT; Rodríguez Acebo W; Martínez Machín G
    Rev Cubana Med Trop; 1998; 50(3):207-8. PubMed ID: 10349445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal capsular polysaccharide-induced modulation of murine immune responses.
    Breen JF; Lee IC; Vogel FR; Friedman H
    Infect Immun; 1982 Apr; 36(1):47-51. PubMed ID: 6210638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a vaccine for Cryptococcus neoformans: principles and caveats.
    Datta K; Pirofski LA
    FEMS Yeast Res; 2006 Jun; 6(4):525-36. PubMed ID: 16696648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.